Australian Clinical Labs Ltd

Australian Clinical Labs Ltd has a debt-to-equity ratio of 1.69, indicating a relatively high level of leverage, and a current ratio of 0.55, suggesting limited short-term liquidity. The company's cash and equivalents amount to 21.44 million AUD, while its long-term debt stands at 290.38 million AUD, resulting in a net cash position that is negative after subtracting total debt. This highlights a potential liquidity risk, as the company may need to rely on operating cash flow to service its debt obligations. In terms of profitability, the company's return on equity (ROE) is 18.93%, which is strong, and its return on assets (ROA) is 5.64%, indicating moderate efficiency in asset utilization. These figures suggest that the company is generating solid returns for its shareholders, although its ROA is below the typical thresholds for high-performing healthcare firms. The company's revenue is primarily concentrated in Australia, with operations in multiple states including Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory. It also offers services under the SunDoctors brand for skin cancer care. However, the input data does not provide specific revenue breakdowns by segment or geography, so the extent of revenue concentration is not quantified. Looking at the company's growth trajectory, the input data does not include forward-looking revenue projections or outlooks for the current or next fiscal year. Analysts have provided a mean price target of 2.57 AUD and a median price target of 2.40 AUD, with a mean recommendation of 2.86, indicating a generally neutral stance. The absence of specific growth metrics or outlooks makes it difficult to assess the company's future performance with certainty. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its liquidity carefully. The dilution risk is low, and there is no indication of dilution potential in the basic shares outstanding, as the basic and diluted shares are the same. Recent events and filings are not detailed in the input data, so there is no information on recent corporate actions, earnings reports, or management commentary. Analysts have issued a range of price targets, with the highest at 3.85 AUD and the lowest at 2.25 AUD, but there are no strong buy recommendations, with only one buy and six hold ratings.